TY  - GEN
AB  - Adeno-­‐associated virus (AAV) is a leading candidate as a gene therapy vector, but as with other vectors, one of the limitations is a host-neutralizing immune response.
AD  - Oregon Health and Science University
AU  - McCraw, Dustin
DA  - 2012-05-01
DO  - 10.6083/M4154F2N
DO  - DOI
ED  - Chapman, Michael
ED  - Advisor
ID  - 763
KW  - Antibodies, Monoclonal
KW  - Epitopes
KW  - Dependovirus
KW  - Tumor Necrosis Factor alpha-Induced Protein 3
KW  - Genetic Therapy
KW  - Antibodies, Monoclonal
KW  - Adenoviridae
KW  - antigenic determinants
L1  - https://digitalcollections.ohsu.edu/record/763/files/766_etd.pdf
L2  - https://digitalcollections.ohsu.edu/record/763/files/766_etd.pdf
L4  - https://digitalcollections.ohsu.edu/record/763/files/766_etd.pdf
LK  - https://digitalcollections.ohsu.edu/record/763/files/766_etd.pdf
N2  - Adeno-­‐associated virus (AAV) is a leading candidate as a gene therapy vector, but as with other vectors, one of the limitations is a host-neutralizing immune response.
PB  - Oregon Health and Science University
PY  - 2012-05-01
T1  - Towards a structural understanding of adeno-associated virus serotype 2 and its recognition by antibodies
TI  - Towards a structural understanding of adeno-associated virus serotype 2 and its recognition by antibodies
UR  - https://digitalcollections.ohsu.edu/record/763/files/766_etd.pdf
Y1  - 2012-05-01
ER  -